BELGRADE, Mont., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, Chief Executive Officer, will present at the Canaccord Musculoskeletal Conference, to be held on Tuesday, March 7, 2023 at 3:30 p.m. Pacific Time in Las Vegas.
A live webcast of the presentation will be available on the Investors section of the Company’s website or through the conference site by using the link below:
Date: Tuesday, March 7, 2023
Time: 3:30 p.m. PT / 6:30 p.m. ET
Webcast: Click Here
A replay of the webcast will be available for approximately 90 days on the Company’s website at www.xtantmedical.com following the conclusion of the presentation.
About Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Investor Relations Contact
Matt Steinberg
Lazar FINN Partners
Ph: 646-871-8481
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.46 |
| Daily Change: | -0.02 -3.19 |
| Daily Volume: | 7,841 |
| Market Cap: | US$63.250M |
November 12, 2024 September 23, 2024 September 18, 2024 August 08, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
